Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agios Pharmaceuticals excels in Q4, eyes hematology franchise expansion

Agios Pharmaceuticals showcased strong performance and progress in its Q4 2022 earnings call, emphasizing advancements in its pipeline and commercial capabilities. While facing challenges in estimating sales and patient enrollment progression, the company is well-positioned to capitalize on opportunities for growth and expansion.

Agios Pharmaceuticals reports robust Q1 earnings and strategic growth outlook

Agios Pharmaceuticals demonstrated strong financial performance, progress in PK activation therapies, and strategic decision-making in Q1 2023.
While facing challenges in distribution and inventory management, the company's focus on persistency, clear milestones, and launch dynamics present growth opportunities.
Overall, Agios Pharmaceuticals is well-positioned to capitalize on its strengths, address challenges, and leverage opportunities for future success.

Agios Pharmaceuticals reports strong Q2 performance and eyes growth opportunities

Agios Pharmaceuticals shows strong financial performance and pipeline progress.
Challenges include slow uptake for PYRUKYND and clinical development queries.
Exciting opportunities lie in potential acquisitions, peak sales targets, and upcoming data readouts.

Agios Pharmaceuticals excels in Q3, poised for growth and innovation

Agios Pharmaceuticals delivered a strong performance in Q3 2023, achieving key milestones and reporting solid financial results, positioning the company for future growth.
With a focus on pipeline advancements, commercial success, and financial stability, Agios demonstrates resilience and potential in the competitive pharmaceutical landscape.
While facing challenges in competitive markets and the need for further clarity on certain aspects, Agios has opportunities to capitalize on its strengths and drive innovation and growth.

Agios Pharmaceuticals reports robust earnings and eyes market expansion

Agios Pharmaceuticals showcased strong performance in PK activator development, with positive data readouts and financial stability driving growth prospects.
While facing challenges in market differentiation and regulatory approval, the company's strategic strengths in rare disease treatments and operational efficiency position it for long-term success.
With upcoming launches for thalassemia and sickle cell disease, Agios has opportunities to expand its market presence, drive revenue growth, and establish itself as a key player in rare disease therapeutics.

Agios Pharmaceuticals excels in Q1, eyes strong growth opportunities

Agios Pharmaceuticals showcased strong performance with positive clinical data and solid financials.
While facing challenges in market dynamics and cost management, the company is optimistic about future opportunities.
With a focus on partnerships and revenue growth, Agios aims to deliver value to shareholders.
The company's robust pipeline and cash position position it well for future success.

Agios Pharmaceuticals reports robust Q3 performance and eyes future launches

Agios Pharmaceuticals showcased strong financial performance and progress in key therapeutic areas during their Q3 2024 earnings call. While facing challenges in addressing analyst inquiries and market comparisons, the company remains optimistic about their future prospects. Leveraging their strengths in market engagement and scientific innovation, Agios is well-positioned for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year.

Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates

– In Partnership with the Sickle Cell Community Consortium, Agios Works to Address Educational Resource Gaps Caused by COVID-19 for Students with Sickle Cell Disease –

Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias

Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q4 2020 Results - Earnings Call Transcript

– Strong Commercial Execution for Second Full Year of TIBSOVO ® with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 –

Agios Reports Fourth Quarter and Full Year 2020 Financial Results

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the following March investor conferences:

Agios to Present at March Investor Conferences

Agios will sell off its oncology business and focus on rare diseases. Its lead drug Mitapivat will file NDAs shortly.

Agios: Back To The Lab

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, February 25, 2021 at 8:00 a.m. ET to report its fourth quarter and year end 2020 financial results and other business highlights.

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021

– 37 Percent of Patients Treated with Mitapivat Achieved ≥33% Reduction in Transfusion Burden Compared to Individual Historical Transfusion Burden Standardized to 24 Weeks (1-Sided p=0.0002) –

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

– Supplemental New Drug Application Planned for Submission in Q1 2021 – – Supplemental New Drug Application Planned for Submission in Q1 2021 –

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. in Q2 2021 and in the EU in Mid-2021 –

Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. ET.

Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

Agios recently sold off its oncology business to Servier for $2B ($1.8B in cash) creating a unique situation to buy a company with a strong drug development track record. With 2 drug approvals under its belt and another one upcoming, there is an opportunity to buy Agios at fair prices.

Agios Pharmaceuticals: A Pivot From Cancer Metabolism To Rare Diseases

Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?

Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases.

Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up

Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.

4 Reasons Agios' Oncology Deal Should Please Investors

Investors applauded the company's planned sale of its oncology portfolio.

Why Agios Pharmaceuticals Stock Is Soaring Today

The announcement that Agios Pharmaceuticals Inc. (NASDAQ: AGIO) will be streamlining its portfolio sent shares sharply higher early Monday.

Agios Pharma's Big Bet on Anemia

Shares of Agios Pharmaceuticals Inc. soared 20.6% in premarket trading on Monday after the company said it is selling its oncology portfolio to Servier, a privately held French pharmaceutical company. Servier will pay $1.8 billion in cash upfront and $200 million in potential future milestone payments for vorasidenib as well as a small percentage of royalties for U.S. net sales of acute myeloid leukemia treatment Tibsovo and U.S. net sales of vorasidenib, if the experimental therapy is approved by the Food and Drug Administration.

Agio's shares jump 20% after announcing plans to sell cancer portfolio

– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building on its Scientific Expertise in Cellular Metabolism and PK Activation to Accelerate and Expand its Genetically Defined Disease Portfolio –

Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties

– Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients , Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP –

Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?

Agios Pharmaceuticals (AGIO) Up 6.2% Since Last Earnings Report: Can It Continue?

Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.

Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the launch of Anemia ID, a program providing no-cost genetic testing for patients with suspected hereditary anemias. The next-generation sequencing panel consists of more than 50 genes and disorders that are known to cause hereditary anemias, including pyruvate kinase deficiency. Patients with hereditary anemia can face a difficult path to a proper diagnosis, and access to comprehensive diagnostic testing is a common barrier to diagnosis. Receiving an accurate diagnosis enables patients and their physicians to better understand their condition and informs disease management decisions.

Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 at 2:00 p.m. ET.

News for Agios Pharmaceuticals Stock (AGIO)